The Drug-induced Pulmonary Hypertension Symposium is taking place in hybrid form (virtual and at Stanford University
The rationale for this symposium is to leverage subject-matter expertise from international academic centers and Stanford University, engage the broader academic communities, global organizations (World Health Organization, United States Food and Drug Administration, European Medicines Agency), and stake-holders (patients, industry partners, etc) to develop a deeper understanding of “drug induced pulmonary hypertension” and establish pharmacovigilance protocols for monitoring drug safety and rapid identification of PH in at-risk populations.
The symposium has an impressive panel of speakers, see at this link on the Stanford website.
Read more about the symposium at this link